# A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

> **NCT03672175** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 581 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** SAGE-217
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03672175
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-19
- **Primary completion:** 2019-09-24
- **Final completion:** 2020-03-17
- **Target enrollment:** 581 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672175, "A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03672175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*